oxyphenbutazone ๐Ÿถ Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
anti-inflammatory analgesics, phenylbutazone derivatives 2036 129-20-4

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • oxyphenbutazone
  • butapirone
  • flamaril
  • oxazolidin
  • oxyphenobutazone
  • oxyphenylbutazone
  • p-Oxyphenylbutazone
A non-steroidal anti-inflammatory drug. Oxyphenbutazone eyedrops have been used abroad in the management of postoperative ocular inflammation, superficial eye injuries, and episcleritis. (From AMA, Drug Evaluations Annual, 1994, p2000) It had been used by mouth in rheumatic disorders such as ankylosing spondylitis, osteoarthritis, and rheumatoid arthritis but such use is no longer considered justified owing to the risk of severe hematological adverse effects. (From Martindale, The Extra Pharmacopoeia, 30th ed, p27)
  • Molecular weight: 324.38
  • Formula: C19H20N2O3
  • CLOGP: 2.72
  • LIPINSKI: 0
  • HAC: 5
  • HDO: 1
  • TPSA: 60.85
  • ALOGS: -3.10
  • ROTB: 5

  • Status: OFM

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
0.30 g O
0.30 g R

ADMET properties:

PropertyValueReference
MRTD (Maximum Recommended Therapeutic Daily Dose) 35.23 ยตM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
S (Water solubility) 1 mg/mL Bocci G, Oprea TI, Benet LZ
BDDCS (Biopharmaceutical Drug Disposition Classification System) 2 Bocci G, Oprea TI, Benet LZ

Approvals:

DateAgencyCompanyOrphan
Dec. 21, 1960 FDA

FDA Adverse Event Reporting System (Female)

None

FDA Adverse Event Reporting System (Male)

None

FDA Adverse Event Reporting System (Geriatric)

None

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC M01AA03 MUSCULO-SKELETAL SYSTEM
ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS
ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS
Butylpyrazolidines
ATC M02AA04 MUSCULO-SKELETAL SYSTEM
TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN
TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN
Antiinflammatory preparations, non-steroids for topical use
ATC S01BC02 SENSORY ORGANS
OPHTHALMOLOGICALS
ANTIINFLAMMATORY AGENTS
Antiinflammatory agents, non-steroids
MeSH PA D000700 Analgesics
MeSH PA D018712 Analgesics, Non-Narcotic
MeSH PA D000893 Anti-Inflammatory Agents
MeSH PA D000894 Anti-Inflammatory Agents, Non-Steroidal
MeSH PA D018501 Antirheumatic Agents
MeSH PA D018373 Peripheral Nervous System Agents
MeSH PA D018689 Sensory System Agents
CHEBI has role CHEBI:33281 antibiotics
CHEBI has role CHEBI:35475 non-steroidal anti-inflammatory agent
CHEBI has role CHEBI:35493 anti-pyretic
CHEBI has role CHEBI:35610 antineoplastic agents
CHEBI has role CHEBI:35845 gout suppressants
CHEBI has role CHEBI:49103 drug metabolites
CHEBI has role CHEBI:76206 xenobiotic metabolites

Drug Use | Suggest Off label Use Form| |View source of the data|

None




๐Ÿถ Veterinary Drug Use

None

๐Ÿถ Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 4.62 acidic
pKa2 7.03 acidic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Cyclooxygenase Enzyme INHIBITOR CHEMBL CHEMBL
fMet-Leu-Phe receptor GPCR WOMBAT-PK
Prostacyclin synthase Enzyme WOMBAT-PK
Nicotinate phosphoribosyltransferase Enzyme Ki 9.52 CHEMBL

External reference:

IDSource
4019078 VUID
N0000147339 NUI
D08324 KEGG_DRUG
4019078 VANDF
C0030078 UMLSCUI
CHEBI:76259 CHEBI
OPB PDB_CHEM_ID
CHEMBL1228 ChEMBL_ID
CHEMBL3989676 ChEMBL_ID
DB03585 DRUGBANK_ID
D010113 MESH_DESCRIPTOR_UI
4641 PUBCHEM_CID
H806S4B3NS UNII
7816 RXNORM
002376 NDDF
387269008 SNOMEDCT_US
49267000 SNOMEDCT_US
7081-38-1 SECONDARY_CAS_RN

Pharmaceutical products:

None